Mesoblast Company Top Insiders
MEOBF Stock | USD 0.19 0.00 0.00% |
Mesoblast employs about 77 people. The company is managed by 29 executives with a total tenure of roughly 176 years, averaging almost 6.0 years of service per executive, having 2.66 employees per reported executive. Examination of Mesoblast's management performance can provide insight into the company performance.
Brian Jamieson Chairman Independent Non-Executive Chairman of the Board |
Eric Strati President Senior Vice President - Commercial |
Mesoblast |
Mesoblast Management Team Effectiveness
The company has return on total asset (ROA) of (0.0688) % which means that it has lost $0.0688 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1581) %, meaning that it generated substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities.Mesoblast Workforce Comparison
Mesoblast is considered to be number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 587,897. Mesoblast adds roughly 77.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Mesoblast Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mesoblast Price Series Summation is a cross summation of Mesoblast price series and its benchmark/peer.
Mesoblast Notable Stakeholders
A Mesoblast stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mesoblast often face trade-offs trying to please all of them. Mesoblast's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mesoblast's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian Jamieson | Independent Non-Executive Chairman of the Board | Profile | |
Eric Strati | Senior Vice President - Commercial | Profile | |
Joshua Muntner | CFO | Profile | |
Paul Hodgkinson | CFO | Profile | |
Shawn Tomasello | Director | Profile | |
Michael Spooner | Non-Executive Director | Profile | |
BenZion Weiner | Non-Executive Independent Director | Profile | |
Silviu Itescu | Executive Director | Profile | |
Donal ODwyer | Non-Executive Director | Profile | |
William Burns | Director | Profile | |
Joseph Swedish | Director | Profile | |
Eric Rose | Non-Executive Director | Profile | |
LLB BCom | Joint Sec | Profile | |
Roger BA | Head Disorders | Profile | |
Peter Howard | General Counsel, Corporate Executive | Profile | |
MS MBA | Chief Officer | Profile | |
BSc LLB | Gen Exec | Profile | |
Geraldine Storton | Head of Regulatory Affairs and Quality Management | Profile | |
MBA MS | Head Partnering | Profile | |
Paul Simmons | Head of Research and New Product Development | Profile | |
Donna Skerrett | Chief Medical Officer | Profile | |
Justin BS | Head Manufacturing | Profile | |
FACP FACRA | CEO, Founder | Profile | |
John McMannis | Head of Manufacturing | Profile | |
Charlie Harrison | Company Secretary | Profile | |
Eric MD | Chief Director | Profile | |
Andrew BCom | Interim Officer | Profile | |
Julie Meldrum | Global Head of Corporate Communications | Profile | |
Schond Greenway | IR Contact Officer | Profile |
About Mesoblast Management Performance
The success or failure of an entity such as Mesoblast often depends on how effective the management is. Mesoblast management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mesoblast management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mesoblast management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 77 people.
The data published in Mesoblast's official financial statements usually reflect Mesoblast's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Mesoblast. For example, before you start analyzing numbers published by Mesoblast accountants, it's critical to develop an understanding of what Mesoblast's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Mesoblast's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mesoblast's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Mesoblast's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mesoblast. Please utilize our Beneish M Score to check the likelihood of Mesoblast's management manipulating its earnings.
Mesoblast Workforce Analysis
Traditionally, organizations such as Mesoblast use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mesoblast within its industry.Mesoblast Manpower Efficiency
Return on Mesoblast Manpower
Revenue Per Employee | 132.6K | |
Revenue Per Executive | 352.1K | |
Net Loss Per Employee | 1.2M | |
Net Loss Per Executive | 3.1M | |
Working Capital Per Employee | 519.5K | |
Working Capital Per Executive | 1.4M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more detail on how to invest in Mesoblast Pink Sheet please use our How to Invest in Mesoblast guide.Note that the Mesoblast information on this page should be used as a complementary analysis to other Mesoblast's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Mesoblast Pink Sheet analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |